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Introduction: Peripheral blood mononuclear cells (PBMC) concentrates collected by apheresis are frequently used
as starting material for cellular therapies, but the cell of interest must often be isolated prior to initiating
manufacturing.
Study design and methods: The results of enriching 59 clinical PBMC concentrates for monocytes or lymphocytes
from patients with solid tumors or multiple myeloma using a commercial closed system semi-automated counter-flow
elutriation instrument (Elutra, Terumo BCT) were evaluated for quality and consistency. Elutriated monocytes (n = 35)
were used to manufacture autologous dendritic cells and elutriated lymphocytes (n = 24) were used manufacture
autologous T cell therapies. Elutriated monocytes with >10% neutrophils were subjected to density gradient
sedimentation to reduce neutrophil contamination and elutriated lymphocytes to RBC lysis.
Results: Elutriation separated the PBMC concentrates into 5 fractions. Almost all of the lymphocytes, platelets
and red cells were found in fractions 1 and 2; in contrast, most of the monocytes, 88.6 ± 43.0%, and neutrophils,
74.8 ± 64.3%, were in fraction 5. In addition, elutriation of 6 PBMCs resulted in relatively large quantities of
monocytes in fractions 1 or 2. These 6 PBMCs contained greater quantities of monocytes than the other 53 PBMCs.
Among fraction 5 isolates 38 of 59 contained >10% neutrophils. High neutrophil content of fraction 5 was
associated with greater quantities of neutrophils in the PBMC concentrate. Following density gradient separation
the neutrophil counts fell to 3.6 ± 3.4% (all products contained <10% neutrophils). Following red cell lysis of the
elutriated lymphocyte fraction the lymphocyte recovery was 86.7 ± 24.0% and 34.3 ± 37.4% of red blood cells
remained.
Conclusions: Elutriation was consistent and effective for isolating monocytes and lymphocytes from PBMC
concentrates for manufacturing clinical cell therapies, but further processing is often required.
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Peripheral blood mononuclear cells (PBMC) concentrates
collected by apheresis are rich in lymphocytes, monocytes
and NK cells and they are a common source of starting
material for the manufacture of cell and gene therapies.
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unless otherwise stated.the manufacture of dendritic cells (DCs), lymphocytes
for cytokine stimulated and genetically engineered T
cell therapies and natural killer (NK) cells for autolo-
gous and allogeneic immunotherapy. They also contain
red blood cells (RBCs), platelets and neutrophils and in
order to consistently produce high quality products, it
is often necessary to isolate monocytes, lymphocytes or
NK cells from PBMC concentrates.
When PBMCs are used as a source of autologous
monocytes to manufacture DCs for cancer or antiviral
immunotherapy the manufacturing process requires thatal Ltd. This is an Open Access article distributed under the terms of the Creative
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The monocytes are then incubated with agents such as
GM-CSF and IL-4 for 3 to 7 days to differentiate them
into immature DCs and with further culture on to
mature DCs [1,2]. A variety of methods can be used to
isolate monocytes from PBMCs, but the manufacturing
of DCs for clinical therapy requires large scale isolation
and the maintenance of the sterility of the cells. One
Good Manufacturing Practices (GMP) method to
isolate monocytes from PBMCs is immunomagnetic
separation using CD14 monoclonal antibodies conju-
gated to magnetic particles in the CliniMACS system
which yields monocytes of more than 90% purity with
recoveries of approximately 65 to 80% [3-6]. The anti-
bodies and sterile disposable kits used in this process
are costly, but despite this limitation many laboratories
use these them to isolate monocytes [3,4] to manu-
facture clinical cell therapies.
Another option for the isolation of monocytes from
PBMC concentrates is continuous counter-flow elu-
triation. Elutriation uses centrifugal force against a
continuously increasing fluid flow to separate cells based
on size and to a lesser extent density. An automated
continuous counter-flow elutriation instrument is avail-
able that has been used primarily to isolate monocytes
from PBMC concentrates, the Elutra system. This
instrument makes use of a closed system sterile plastic
disposable kit that allows for the sterile processing of the
cells [7-11]. The PBMC concentrate is loaded into the
elutriator and cells are collected in 5 fractions. Typically,
lymphocytes and red blood cells are found in earlier
factions and neutrophils and monocytes in the later frac-
tions. The cost of isolating monocytes using elutriation
is less than that of using antibodies and magnetic beads.
We have been using elutriation to enrich monocytes
from PBMC concentrates to manufacture DCs for
clinical vaccine studies.
PBMC concentrates are also used as a source of allo-
geneic lymphocytes from hematopoietic stem cell (HSC)
transplant donors to treat patients with disease relapse
following HSC transplantation; furthermore autologous
PBMCs are used as a source of lymphocytes for adoptive
immunotherapy of cancer. Aliquots of unprocessed PBMC
concentrates can often be used for donor lymphocyte
infusions, but for adoptive immunotherapy, lympho-
cytes generally must be free from contaminating RBCs
and neutrophils. Immunomagnetic selection with CD3,
CD4 or CD8 monoclonal antibodies conjugated to
magnetic particles can also be used to select or deplete
T cells or specific subsets of T cells [12-15]. We have
been using counter-flow elutriation to isolate autolo-
gous lymphocytes for adoptive immune therapy. Since
the elutriated fractions that contain lymphocytes also
contain RBCs, we treat the elutriated lymphocytes toreduce RBC contamination prior to beginning lympho-
cyte culture.
While elutriation has been used to enrich for and
separate monocytes [10,16] and lymphocytes [17] for
clinical applications, little information is available on
the consistency and quality of monocyte and lympho-
cyte concentrates obtained from PBMC concentrates
collected for autologous clinical therapy. We summa-
rized our experience using an automated instrument to
elutriate 59 PBMC concentrates, which were processed
to enrich for either monocytes to manufacture clinical
DC products or lymphocytes to manufacture T cell
products for clinical immunotherapy.
Methods
Study design
Subjects were enrolled in IRB-approved protocols that
made use of mature DCs to treat adults with prostate or
other advanced cancers or rapamycin-generated Th1/
Tc1 lymphocytes [18,19] to treat patients with multiple
myeloma. After obtaining informed consent, PBMCs were
collected from subjects using a blood cell separator. The
PBMC concentrates were elutriated with a semi-
automatic counter-flow elutriator. All products elutri-
ated from patients enrolled in three clinical protocols
from May 2010 through December 2013 were studied.
When monocytes isolated by elutriation were being
used to manufacture DCs, if the proportion of neutro-
phils in the monocytes obtained from the elutriator
was greater than 10%, the product was further enriched
for monocytes using density gradient separation. When
lymphocytes isolated by elutriation were used to
manufacture clinical cell therapies, contaminating red
blood cells were lysed using ammonium chloride.
PBMC concentrate collection
PBMC concentrates were collected using a blood cell
separator (COBE Spectra Apheresis System, Terumo
BCT, Lakewood, Colorado, USA) by processing 8 to 12
liters of whole blood.
Elutriation
The PBMC concentrates were subject to elutriation
using a semi-automatic counter-flow elutriation instru-
ment (Elutra Cell Separation System, version 1.1, Ter-
umo BCT) using a user defined profile. Our procedure
required that the quantity of white blood cells loaded
into the Elutra be at least 5×109 cells but not more than
20×109 cells. The program for the collection of mono-
cytes collects cells in 5 fractions. The chamber rotation
speed was maintained at 2400 RPMs for fractions 1
through 4 and the media flow rate was maintained at
60 ml/min for fraction 1, 120 ml/min for fraction 2,
122 ml/min for fraction 3 and 124 ml/min for fraction 4.
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they were collected with the rotor turned off.
Density gradient separation
The leukocytes were pelleted by centrifugation (350×g)
for 10 minutes and resuspended in Hank’s Balance Salt
Solution (HBSS) (Lonza, Walkersville, MD) at a concen-
tration of 1-2×108 cells per mL. Density gradient separ-
ation was performed by placing 40 mL of leukocyte
suspension in a 50 ml conical tube and underlying cells
with 10 mL of Ficoll/Hypaque [BioWhittaker Lympho-
cyte Separation Medium, Ficoll and sodium diatrizoate
(Hypaque), density 1.077, Lonza]. After centrifugation at
835×g for 25 minutes the mononuclear cells were re-
moved, washed (675×g, for 10 minutes) and resuspended
in HBSS.
RBC lysis
After pelleting the cells, they were incubated for 7 to
10 minutes with ACK Lysing Buffer (Lonza, Walkersville,
MD) and then washed and resuspended in 0.9% saline
(B.Braun Medical Inc., Irvine, CA) with 0.3% trisodium
citrate (TriCitrasol anticoagulant sodium citrate concen-
trate 46.7%, Citra Labs, Braintree, MA).
Cell counts
Blood counts were measured using automated hematology
analyzer (Cell-Dyn 3700).
Statistically analysis
The values shown are mean ± 1 standard deviation
unless otherwise indicated. Groups were compared using
t-tests (Microsoft Excel, Microsoft Inc., Redmond, WA).
Results
Subjects studied
A total of 59 autologous elutriated PBMC concentrates
were studied which were collected from 51 subjects:
PBSCs were collected from 6 subjects twice and 1 sub-
ject three times. Elutriated monocytes from 35 PBMC
concentrates were used to manufacture autologous DCs
for immunotherapy of cancer and elutriated lymphocytesTable 1 Composition of 59 clinical PBMC concentrates loaded
recovered fractions
WBCs (×109) RBCs (×109) Platelets (×109)
Loaded 15.4 ± 4.2 199.9 ± 109.0 469.5 ± 194.2
Fraction 1 5.04 ± 3.27 190.3 ± 123.9 349.8 ± 241.3
Fraction 2 3.82 ± 2.07 58.4 ± 87.9 10.3 ± 60.4
Fraction 3 0.38 ± 0.34 3.14 ± 1.90 >0.100
Fraction 4 0.29 ± 0.30 0.95 ± 1.11 0.13 ± 0.52
Fraction 5 4.16 ± 2.07 0.63 ± 1.46 0.16 ± 0.26
The values shown are mean ± 1 standard deviation.from 24 PBMC concentrates were used to manufacture
rapamycin-generated Th1/Tc1 lymphocytes cells for
adoptive cell therapy following autologous transplant-
ation of patients with multiple myeloma. 35 subjects
were male and 16 were female and 42 were White, 7
were African American, 1 was mixed and for 1 the race
was not known. The median age of the subjects was
59.3 years and ranged from 35.7 to 77.3 years.
Composition of elutriated fractions
Analysis of all 59 elutriated PBMC concentrates found
that the majority of leukocytes were found in fractions 1,
2 and 5 (Table 1). Almost all of the lymphocytes were
found in fractions 1 and 2, 45.8 ± 24.8% and 35.1 ± 16.9%
respectively, and almost all of the monocytes, 88.6 ±
43.0%, and neutrophils, 74.8 ± 64.3%, were in fraction 5.
The lymphocyte rich fractions 1 and 2 contained almost
all of the RBCs and platelets.
The separation of neutrophils and lymphocytes was
more consistent than that of monocytes. For all 59 elu-
triated PBMC concentrates fractions 1 through 4 con-
tained less than 1×109 neutrophils (Figure 1A) and
fractions 4 and 5 contained less than 1×109 lymphocytes
(Figure 1A) but fraction 3 from one PBMC concentrate
contained more than 1×109 lymphocytes. However, frac-
tions 1 and/or 2 from 6 PBMC concentrates contained
more than 1×109 monocytes (Figure 1C). For these 6
PBMC concentrates the quantities of monocytes in each
of the 5 fractions is shown in Figure 2. A comparison of
these 6 PBMC concentrates with the 53 concentrates
with less than 1×109 monocytes in fractions 1 through 4
found that the 6 PBMCs contained greater quantities of
total white blood cells (18.3 ± 0.88×109 versus 15.0 ±
4.28×109, p < 0.035) and monocytes (5.07 ± 2.55×109 ver-
sus 2.92 ± 1.65×109, p = 0.0073) but similar quantities of
neutrophils, lymphocytes, platelets and RBCs.
Our clinical DC manufacturing protocols use fraction
5 as a source of starting material for manufacturing
DCs. While the majority of leukocytes in the 5 fraction
were monocytes (68.1 ± 22.4%), a large quantity of neu-
trophils were present (24.8 ± 23.1%). Our protocols re-
quire that monocytes used to manufacture DCs containinto the counter-flow elutriation instrument and the 5
Neutrophils (×109) Lymphs (×109) Monos (×109)
1.81 ± 1.90 9.97 ± 3.28 3.14 ± 1.88
>0.100 4.68 ± 3.00 0.180 ± 0.316
>0.100 3.45 ± 1.94 0.299 ± 0.425
>0.100 0.26 ± 0.27 0.11 ± 0.21
>0.100 0.12 ± 0.11 0.17 ± 0.27






























































Figure 1 Separation of neutrophils, lymphocytes and monocytes by counter-flow elutriation. The results of the separation of neutrophils
(panel A), lymphocytes (panel B) and monocytes (panel C) from 59 PBMC concentrates into fractions 1, 2, 3, 4 and 5) are shown. Each symbol
represents one fraction from each of the 59 PBMC concentrates. Values are expressed as 109 cells.
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trates in this study, 35 were used to manufacture DCs
and only 12 of the 35 fraction 5′s (34%) contained 10%
or less neutrophils. The 23 fraction 5′s with >10% neu-
trophils were subjected to density gradient separation
over ficoll to separate the monocytes and neutrophils.
Following ficoll density gradient separation all 23 prod-
ucts contained less than 10% neutrophils and few mono-
cytes were lost (Table 2).
When all 59 PBMC concentrates were considered, a
comparison of the quantities of the various types of
cells among the 38 concentrates that yielded fraction5′s with >10% neutrophils and the 21 whose fraction
5′s yielded ≤10% revealed that PBMC concentrates
yielding >10% neutrophils in fraction 5 contained signifi-
cantly more neutrophils (Table 3). There were no other
significant differences among the two groups of products.
We also used elutriation to isolate lymphocytes from
PBMC products that are used to manufacture Th1/Tc1
cells. Fraction 2 or fraction 2 plus fraction 1 are used.
Both fractions 1 and 2 contain large quantities of lym-
phocytes with few other leukocytes, but fraction 2 con-
tains fewer RBCs and platelets and is the preferred




























Figure 2 Quantity of monocytes in each of the 5 fractions elutriated from 6 PBMC concentrates with large quantities of
monocytes in fractions 1 or 2. Results of elutriating 6 PBMC concentrates 15 (♦), 27(■), 33(▲), 42(×), 49(*), and 59(●) are shown. Values are
expressed as 109 cells.
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fractions are often used. Among the products studied,
24 were used to manufacture rapamycin-generated Th1/
Tc1 lymphocytes cells; for 7 products only fraction 2 was
used for further manufacture and for 17 products,
fractions 1 and 2 were used. All 24 elutriated lympho-
cytes used for further manufacturing were subjected to
ammonium chloride RBC lysis which was effective at
removing RBCs with little loss of lymphocytes. Recovery
of WBCs following RBC lysis was 86.7 ± 24.0% and 34.3 ±
32.4% of the RBCs remained.
Comparison of elutriated products among subjects
Among the 59 elutriated PBMC concentrates, 28 were
from men with stage 0 prostate cancer whose only
measure of disease was a rising Prostate Specific Antigen
(PSA) (biochemical recurrence) and the other 31 prod-
ucts were from patients with either multiple myeloma or
various advanced solid cancers. In general, the health of
the patients with prostate cancer was better than that of
the other patients. To determine if the condition of
people donating PBMC concentrates influenced the ef-
fectiveness of the counter-flow elutriation process weTable 2 Results of density gradient separation from elutriate
WBCs (×109) Neutrophils (×109) Lymphs (×109)
Pre-Ficoll 4.33 ± 2.33 1.85 ± 2.08 0.16 ± 0.13
Post-Ficoll 2.47 ± 0.95 0.10 ± 0.12 0.08 ± 0.09
The values shown are mean ± 1 standard deviation.compared the composition of the cells loaded into the
elutriation instrument and the elutriated fractions
among these two groups. Fraction 5 from patients with
multiple myeloma and advanced cancers had signifi-
cantly more monocytes and lymphocytes but similar
number of neutrophils (Table 4). This is likely a result of
loading the elutriator with slightly more WBCs and
monocytes from patients with multiple myeloma and
advanced cancer. The proportion of leukocytes in frac-
tion 5 that were neutrophils were similar for patients
with prostate cancer and multiple myeloma/advanced
cancer (25.9 ± 22.1% versus 23.9 ± 23.9%, p = 0.75
respectively) as were the proportion of monocytes
(68.6 ± 22.0% versus 67.5 ± 22.8%; p = 0.85). Among 28
elutriated PBMC concentrates from men with prostate
cancer, 2 contained more than 1×109 monocytes in
fractions 1 or 2 and among the 31 from patients with
multiple myeloma or advanced cancer 4 contained
more than 1×109 monocytes.
Discussion
We used an automated counter-flow elutriation instru-
ment to enrich monocytes from PBMC concentrates tofraction 5 (n = 23)
Monos (×109) Neutophils (%) Lymphs (%) Monos (%)
2.27 ± 0.89 35.0 ± 19.8 3.6 ± .2.9 59.4 ± 19.2
2.24 ± 0.84 3.61 ± 3.37 3.61 ± 7.34 91.0 ± 4.06
Table 3 Comparison of elutriated PBMC concentrates that yielded elutriated fraction 5s with >10% neutrophils and
those with ≤10% neutrophils
Composition of PBMC products loaded
Neutrophils in Fraction 5 N WBCs (×109) RBCs (×109) Platelets (×109) Neutrophil (×109) Lymphs (×109) Monos (×109)
>10% 38 15.6 ± 4.0 200.4 ± 120.1 459.6 ± 204.6 2.30 ± 1.91* 9.79 ± 3.26 3.18 ± 1.84
≤10% 21 14.9 ± 4.5 199.9 ± 85.2 488.9 ± 172.7 0.91 ± 1.51 10.30 ± 3.30 3.06 ± 1.93
The values shown are mean ± 1 standard deviation.
*p <0.01.
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generated Th1/Tc1 lymphocytes for autologous adoptive
immunotherapy. When PBMC concentrates from pa-
tients with prostate cancer, multiple myeloma and
other advanced malignancies were processed with the
elutriation instrument, lymphocytes were easily, con-
sistently and cost effectively separated from mono-
cytes. Almost all monocytes were found in fraction 5
and almost all lymphocytes were present in fractions 1
and 2. However, almost all neutrophils were also found
in fraction 5 with monocytes and almost all RBCs were
in fractions 1 and 2 with lymphocytes. These results
are similar to those of other reports which evaluated
the same instrument to isolate monocytes from small
numbers of PBMC concentrates collected from healthy
subjects [7,9,11,20-23], pooled whole blood buffy coat
products [8,24] and PBMCs from up to 24 patients
with cancer [10,11,16].
We found that the separation of monocytes was less
consistent than that of lymphocytes and neutrophils. For
10% of the PBMC concentrates elutriation resulted in
the distribution of relatively large quantities of monocytes
into fractions 1 or 2. This was not a failure to separate
monocytes since significant quantities of monocytes were
also found in fraction 5. The fact that PBMCs concen-
trates with large quantities of monocytes in fractions 1 or
2 contained larger quantities of white blood cells and
monocytes suggest that loading too many monocytes into
the elutriation instrument may result in suboptimal
monocyte separation. Our elutriation protocol limited the
number of white blood cells loaded to ≤ 20×109 cells butTable 4 Comparison of PBMC cellular content relative to elut
cancer and multiple myeloma and other advanced stage canc
n WBCs (×109) RBCs (×109) Platelet
Loaded
Prostate Cancer 28 14.1 ± 4.5 212.6 ± 130.2 524.9 ± 1
Multiple Myeloma* 31 16.6 ± 3.6# 188.4 ± 83.7 421.3 ± 1
Fraction 5
Prostate Cancer 28 3.59 ± 2.18 1.02 ± 1.88 0.24 ± 0.
Multiple Myeloma* 31 4.66 ± 1.81$ 0.28 ± 0.76 0.09 ± 0.
The values shown are mean ± 1 standard deviation.
*Includes patients with multiple myeloma and cancers other than prostate cancer.
#p < 0.05 for comparison of the quantity of cells loaded in the elutriator among pat
$p < 0.05 for comparison of the quantity of cells in fraction 5 among patients with pthere were no upper limits on the quantity of monocytes
loaded.
While counter-flow elutriation was consistent and ef-
fective at separating lymphocytes and monocytes, the
elutriated cells of interest commonly require further pro-
cessing before they could be placed into culture. In order
to ensure consistent manufacturing of DCs from mono-
cytes, our manufacturing protocols require that the
monocytes used for starting material contain less than
or equal to 10% neutrophils. We found that only about
one-third of the products met these criteria, but the
quantity of neutrophils among the monocytes could be
reduced greatly by density gradient separation with little
loss of monocytes. We investigated factors that might in-
fluence the neutrophil content of the elutriated mono-
cytes and found that the portion of neutrophils in the
monocyte rich fraction 5 was dependent on the quantity
of neutrophils loaded into elutriator at the onset of the
process; this result is similar to the findings of Chen
et al. [10]. While we elected to deplete neutrophils from
some elutriated monocytes, others have reported that
the presence of as much as 20% to 30% neutrophils in
elutriated monocytes used to manufacture DCs does not
affect the quality of the final mature DC product [24]. If
we would have used >30% as criteria for neutrophil re-
duction, 19 (32%) of the fraction 5 isolates would, still
have required further density gradient separation.
When the counter-flow elutriator was used to enrich
lymphocytes from PBMC concentrates, we used the
lymphocyte rich fractions 1 or 2 or only fraction 2, de-
pending on the quantity of lymphocyte required. However,riated fraction 5 from patients with early stage prostate
ers
s (×109) Neutrophils (×109) Lymphs (×109) Monos (×109)
96.5 1.56 ± 1.69 9.66 ± 3.39 2.58 ± 1.49
78.7# 2.03 ± 2.04 10.3 ± 3.15 3.64 ± 2.04#
29 1.29 ± 1.99 0.086 ± 0.09 2.11 ± 0.81
20$ 1.32 ± 1.54 0.22 ± 0.20$ 2.98 ± 1.22$
ients with prostate cancer and multiple myeloma and other advanced cancers.
rostate cancer and multiple myeloma and other advanced cancers.
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taining approximately 3 times more RBCs than fraction 2.
In order to obtain RBC-depleted lymphocytes, the desired
fractions were treated with ACK lyse solution to lyse con-
taminating RBCs. This process reduced the number of
RBCs approximately 3-fold with only a small reduction of
lymphocyte quantity. In most cases the isolated lympho-
cytes were cryopreserved prior to manufacturing the
rapamycin-generated Th1/Tc1 lymphocytes. This freeze/
thaw cycle resulted in further lysis and depletion of RBCs
(data not shown).
While both density gradient separation and RBC lysis
were effective at increasing the purity of the elutriated
monocytes and lymphocytes, they required the use of
additional reagents and staff time. In addition, both
density gradient separation and lysis procedures were
semi-open manual processes which increased the risk of
microbial contamination of the final product. Ideally, it
would be best to avoid further processing of monocytes
and lymphocytes isolated by counter-flow elutriation by
collecting PBMC concentrates that have very low quan-
tities of neutrophils and RBCs, but this was not always
possible. The quantities of neutrophils and RBCs con-
taminating PBSC concentrates collected by apheresis is
dependent on several factors including the donors neu-
trophil count, RBC characteristics, duration of the
apheresis procedure and characteristics of the blood cell
separator. All blood cell separators collect some neutro-
phils and RBCs with the lymphocytes and monocytes
[25,26] and the quantities of neutrophils and RBCs col-
lected increases as the volume of blood processed during
the apheresis procedure increases. The DC manufactur-
ing protocols require relatively large quantities of mono-
cytes and hence a relatively large volume of blood was
processed and large quantities of neutrophils are col-
lected. The quantities of neutrophils collected with lym-
phocytes and monocytes are dependent to some degree
on the blood cell separator. The Fenwal CS3000 was
more efficient at collecting mononuclear cells, but it is
no longer available [25]. The blood cell separator we
used in this study is only partially automated; a new
more highly automated blood cell separator is becoming
available which may be able to collect PBMC concen-
trates with a greater proportion of monocytes [26] and
hence would require a shorter collection duration result-
ing in PBMC concentrates with fewer contaminating
and neutrophils.
Conclusions
Elutriation is effective for isolating monocytes from
PBMC concentrates for DC manufacture, but the elutri-
ated monocyte fraction often required further processing
to reduce the neutrophil content. Elutriation was also ef-
fective at obtaining lymphocytes from PBSC concentrates,but all lymphocytes fractions contained RBCs and an RBC
lysis step was also required prior to initiating cultures.
The separation of monocytes was less consistent that of
lymphocytes and inefficient separation was associated with
loading the elutriator with large quantities of monocytes.
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